NZ594178A - An ex vivo method of predicting toxicity to tyrosine kinase inhibitors - Google Patents

An ex vivo method of predicting toxicity to tyrosine kinase inhibitors

Info

Publication number
NZ594178A
NZ594178A NZ594178A NZ59417807A NZ594178A NZ 594178 A NZ594178 A NZ 594178A NZ 594178 A NZ594178 A NZ 594178A NZ 59417807 A NZ59417807 A NZ 59417807A NZ 594178 A NZ594178 A NZ 594178A
Authority
NZ
New Zealand
Prior art keywords
drug
tyrosine kinase
cell
vivo method
kinase inhibitors
Prior art date
Application number
NZ594178A
Other languages
English (en)
Inventor
Sarah S Bacus
Original Assignee
Targeted Molecular Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targeted Molecular Diagnostics Llc filed Critical Targeted Molecular Diagnostics Llc
Publication of NZ594178A publication Critical patent/NZ594178A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
NZ594178A 2006-02-27 2007-02-27 An ex vivo method of predicting toxicity to tyrosine kinase inhibitors NZ594178A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US77709606P 2006-02-27 2006-02-27
US82123006P 2006-08-02 2006-08-02
US82737206P 2006-09-28 2006-09-28
US82834506P 2006-10-05 2006-10-05
US86773606P 2006-11-29 2006-11-29
PCT/US2007/062871 WO2007101191A2 (en) 2006-02-27 2007-02-27 Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
NZ594178A true NZ594178A (en) 2013-02-22

Family

ID=38459790

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ594178A NZ594178A (en) 2006-02-27 2007-02-27 An ex vivo method of predicting toxicity to tyrosine kinase inhibitors
NZ571465A NZ571465A (en) 2006-02-27 2007-02-27 Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ571465A NZ571465A (en) 2006-02-27 2007-02-27 Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors

Country Status (11)

Country Link
US (2) US8709738B2 (https=)
EP (1) EP1996939B1 (https=)
JP (2) JP5539653B2 (https=)
KR (1) KR101390625B1 (https=)
CN (2) CN101438155B (https=)
AU (1) AU2007220094B2 (https=)
CA (1) CA2643846A1 (https=)
ES (1) ES2475162T3 (https=)
IL (1) IL193715A (https=)
NZ (2) NZ594178A (https=)
WO (1) WO2007101191A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
WO2015027171A1 (en) * 2013-08-23 2015-02-26 Quintiles Transnational Corporation Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway
EP3739041A1 (en) 2014-03-27 2020-11-18 The Salk Institute for Biological Studies Compositions and methods for treating type 1 and type 2 diabetes and related disorders
AU2016225076B2 (en) 2015-02-27 2018-09-13 Salk Institute For Biological Studies Reprogramming progenitor compositions and methods of use therefore
AU2017269364B2 (en) 2016-05-25 2023-08-31 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling
JP7032723B2 (ja) * 2017-07-21 2022-03-09 公立大学法人福島県立医科大学 薬剤の心毒性評価方法及びそのための試薬又はキット
WO2019084395A1 (en) * 2017-10-27 2019-05-02 University Of Virginia Patent Foundation COMPOUNDS AND METHODS FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
TWI711458B (zh) * 2019-07-08 2020-12-01 大江生醫股份有限公司 植物發酵物及其製備方法與用於胃臟保健的用途
KR102493664B1 (ko) 2020-01-29 2023-02-01 한국화학연구원 심장 독성 예측 모델링 시스템 및 모델링 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
CA2459508A1 (en) * 2001-09-24 2003-04-03 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data
JP4611025B2 (ja) * 2002-11-04 2011-01-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 体内のブドウ糖または脂肪酸の代謝に関する高処理量測定のための重水素化ブドウ糖または脂肪の耐性試験
EP1980629A3 (en) 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers

Also Published As

Publication number Publication date
KR20090008194A (ko) 2009-01-21
CN103217520A (zh) 2013-07-24
EP1996939A2 (en) 2008-12-03
AU2007220094B2 (en) 2013-12-05
EP1996939A4 (en) 2009-07-15
JP5539653B2 (ja) 2014-07-02
IL193715A (en) 2014-06-30
KR101390625B1 (ko) 2014-04-29
WO2007101191A2 (en) 2007-09-07
NZ571465A (en) 2011-09-30
CN101438155A (zh) 2009-05-20
EP1996939B1 (en) 2014-03-26
WO2007101191A3 (en) 2007-12-13
JP2009533017A (ja) 2009-09-17
CA2643846A1 (en) 2007-09-07
ES2475162T3 (es) 2014-07-10
US20090186910A1 (en) 2009-07-23
JP2013063090A (ja) 2013-04-11
CN101438155B (zh) 2013-04-24
US20130288285A1 (en) 2013-10-31
US8709738B2 (en) 2014-04-29
AU2007220094A1 (en) 2007-09-07
IL193715A0 (en) 2009-05-04

Similar Documents

Publication Publication Date Title
NZ594178A (en) An ex vivo method of predicting toxicity to tyrosine kinase inhibitors
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
MX2009002496A (es) Combinaciones que contienen un derivado de 4-acilaminopiridina.
IL187509A0 (en) Raf inhibitor compunds and methods of use thereof
BRPI0413363A (pt) formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
EP2120956A4 (en) METHODS FOR PREVENTING OR REDUCING THE NUMBER OF DROUGHT ERYTHEMES USING XANTHINE OXYDOREDUCTASE INHIBITORS AND INFLAMMATORY AGENTS
PT1876129E (pt) Processo e dispositivo para a redução do consumo de energia de uma instalação de elevadores
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
TW200639163A (en) RAF inhibitor compounds and methods
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
IL192634A0 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2007143146A3 (en) Method of treating inflammatory diseases using tyroskine kinase inhibitors
ZA200807862B (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MX2008009579A (es) Metodo para el tratamiento de dolor neuropatico.
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
EP2266561A3 (en) IKK Inhibitors for the Treatment of Endometriosis
TWI351035B (en) Low-power dram and method for driving the same
NZ571858A (en) Methods of treating, reducing and inhibiting the appearance of ageing in the skin
TW200638950A (en) Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE493485T1 (de) Hochtemperaturkorrosionsinhibitor
IL198286A0 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
WO2008051793A3 (en) Method of preventing or treating metabolic syndrome
MX2009003102A (es) INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA.
AU318444S (en) Retainer for rust inhibitor
EP1881756A4 (en) TREATMENT OF DISEASES OF THE MICROVASCULAR SYSTEM WITH ACETYLCHOLINESTERASE INHIBITORS

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 FEB 2014 BY CPA GLOBAL

Effective date: 20130718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 FEB 2017 BY CPA GLOBAL

Effective date: 20140116

LAPS Patent lapsed